Sam Ulin

Partner
ClearView Healthcare Partners

Sam Ulin is a Partner at ClearView Healthcare Partners, where he serves as a senior leader and strategic advisor to executive teams across the life sciences industry. He is a member of the firm’s Executive Committee and leads ClearView’s Marketing and Go-To-Market functions, guiding the growth and positioning of the leading strategic consultancy in the life sciences space.

Sam’s expertise spans metabolic health, immunology, and neuroscience, and he is particularly recognized for his leadership in the obesity sector. His practice bridges clinical innovation, commercial strategy, and enterprise value—connecting the science behind therapeutic performance to the portfolio, transaction, and commercialization frameworks required to drive global adoption and long-term value creation. For more than 15 years, he has focused on the obesity landscape, leading lifecycle management and buy-side and sell-side transaction support for more than 20 distinct assets that have collectively impacted the care for tens of millions of patients worldwide.

His recent work centers on the future of commercialization, with a particular emphasis on Direct-to-Patient (DTP) models and the use of precision consumer data to reshape how biopharma companies engage patients, providers, and payers at scale while maximizing both impact and efficiency.

Beyond his role at ClearView, Sam is an active early-stage investor and company advisor. He partners with founders to shape clinical development, financing, and commercial positioning, focusing on emerging assets and platforms as they transition from preclinical innovation to first-in-human validation.

Prior to consulting, Sam conducted graduate research in stem cell biology. He earned his ScB with Honors in Biochemistry from Brown University and his MS in Molecular Biology from the University of California, San Diego.